---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-046108"
form_type: "8-K"
ticker: "CYPH"
cik: "0001509745"
company_name: "CYPHERPUNK TECHNOLOGIES INC."
filed_at: "2024-04-11T23:59:59+00:00"
generated_at: "2026-06-04T00:01:00.834079+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Leap Therapeutics raises $40M in private placement to fund DKN-01 clinical trials

## Summary
- Gross proceeds ~$40M from sale of 12.66M shares at $2.82 and pre-funded warrants for 1.52M shares at $2.819.
- Financing expected to close April 15, 2024; investors include Gilead Sciences and other institutional investors.
- Proceeds to expand DeFianCe colorectal cancer study from 130 to 180 patients and advance DisTinGuish gastric cancer study.
- Cash runway extended into Q2 2026; funds also used for Phase 3 readiness manufacturing and working capital.

## SEC filing metadata
- accession: 0001104659-24-046108
- form_type: 8-K
- ticker: CYPH
- cik: 0001509745
- company_name: CYPHERPUNK TECHNOLOGIES INC.
- filed_at: 2024-04-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509745/000110465924046108/0001104659-24-046108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509745/000110465924046108/tm2411534d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-046108
- JSON: https://secwatch.observer/filing/0001104659-24-046108.json
- Plain text: https://secwatch.observer/filing/0001104659-24-046108.txt

## Key facts
- Material Agreements
  CYPHERPUNK TECHNOLOGIES INC. entered into Securities Purchase Agreement with certain institutional investors valued at approximately $40 million (effective 2024-04-10).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Value: approximately $40 million
  - Effective: 2024-04-10
  source text: On April 10, 2024, Leap Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain institutional investors (collectively, the “Purchasers,” and each, a “Purchaser”) providing for a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to which the Company expects to issue and sell to the Purchasers an aggregate of (a) 12,660,993 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price per Share equal to $2.82, and (b) pre-funded warrants, in the form attached to the Securities Purchase Agreement as Exhibit B (the “Pre-Funded Warrants”), to purchase 1,523,404 shares of Common Stock (such shares of Common Stock issuable upon exercise of the Pre-Funded Warrants, the “Warrant Shares”), at a purchase price per Pre-Funded Warrant equal to (i) $2.819 (which is equal to the price
  evidence_url: https://www.sec.gov/Archives/edgar/data/1509745/000110465924046108/0001104659-24-046108-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.